The FDA approval of denileukin diftitox (Lymphir) marked a significant shift in this paradigm. As a first-in-class immunotoxin, it employs a dual-action mechanism: directly targeting interleukin-2 (IL ...

Researchers at the Johns Hopkins Kimmel Cancer Center's Ludwig Center developed a new treatment that selectively targets ...

The National Institute for Health and Care Excellence (NICE) has approved a chimeric antigen receptor (CAR) T-cell therapy for adults with large B-cell lymphoma. The treatment significantly delays ...

A next-generation, anti-CD19 enhanced CAR T-cell therapy that secretes interleukin-18 achieved a response in 81% of lymphoma patients who failed previous CAR T-cell therapy. Duration of response was 9 ...

The use of bispecific antibodies (BsAb) before chimeric antigen receptor T-cell therapy (CAR-T) appeared to be a more optimal ...

Fred Locke, MD, Moffitt Cancer Center, explains why this hematologic cancer is such an attractive target for chimeric antigen receptor (CAR) T-cell therapy, specifically allogeneic, which uses healthy ...

In the treatment of non-Hodgkin lymphoma with CD19 chimeric antigen receptor (CAR) T-cell therapy, baseline kidney function did not appear to be associated with an increased risk of developing acute ...

Burkitt's lymphoma is a rare and aggressive blood cancer characterized by a translocation of the MYC gene. It occurs most ...

Clinical study from Baylor College of Medicine demonstrates a favorable safety profile and up to 84.6% disease control rate in patients with ...

Brexucabtagene autoleucel approval marked a significant advancement in MCL treatment, achieving a 62% complete remission rate in resistant or relapsed patients. Prognostic tools like the Ki-67 index ...